Skip to Main Content

Advertisement

Skip Nav Destination

CCR Focus Archive 2008


CCR Focus Archive Home


2017  |  2016  |  2015  |  2014  |  2013  |  2012  |  2011  |  2010  |  2009  |  2008  |  2007  |  2006


Breast Cancer: Pathways to Personalized Medicine (December 15, 2008)
Phase 0 Trials (June 15, 2008)
Unraveling an Enigma: Biostatistics and Biomarkers (October 1, 2008)
New Cytotoxics in Oncology (March 15, 2008)
Navigating Early Translational Cancer Research (September 15, 2008)

2008 CCR Focus Sections


CCR Focus Cover

Breast Cancer: Pathways to Personalized Medicine
December 15, 2008
Guest Editor: Funmi Olopade, 14 (24) : 7969–8334

From the Editor
Susan E. Bates

Advances in Breast Cancer: Pathways to Personalized Medicine
Olufunmilayo I. Olopade, Tatyana A. Grushko, Rita Nanda, and Dezheng Huo

Genetic Susceptibility Loci for Breast Cancer by Estrogen Receptor Status
Montserrat Garcia-Closas and Stephen Chanock

Triple-Negative Breast Cancer: Risk Factors to Potential Targets
Bryan P. Schneider, Eric P. Winer, William D. Foulkes, Judy Garber, Charles M. Perou, Andrea Richardson, George W. Sledge, and Lisa A. Carey

Emerging Biomarkers and New Understanding of Traditional Markers in Personalized Therapy for Breast Cancer
Mitch Dowsett and Anita K. Dunbier

Pharmacogenetics in Breast Cancer Therapy
Sing-Huang Tan, Soo-Chin Lee, Boon-Cher Goh, and John Wong

Back to top


CCR Focus Cover

Unraveling an Enigma: Biostatistics and Biomarkers
October 1, 2008
Guest Editor: Stephen George, 14 (19) : 5939–6349

From the Editor
Susan E. Bates

Statistical Issues in Translational Cancer Research
Stephen L. George

Statistical Challenges in Preprocessing in Microarray Experiments in Cancer
Kouros Owzar, William T. Barry, Sin-Ho Jung, Insuk Sohn, and Stephen L. George

Validation of Analytic Methods for Biomarkers Used in Drug Development
Cindy H. Chau, Olivier Rixe, Howard McLeod, and William D. Figg

Validation of Biomarker-Based Risk Prediction Models
Jeremy M.G. Taylor, Donna P. Ankerst, and Rebecca R. Andridge

The Use of Genomics in Clinical Trial Design
Richard Simon

Back to top


CCR Focus Cover

Navigating Early Translational Cancer Research
September 15, 2008
Guest Editor: Ernest Hawk, Lynn Matrisian, and William Nelson, 14 (18) : 5643–5937

From the Editor
Susan E. Bates

The Translational Research Working Group Developmental Pathways: Introduction and Overview
Ernest T. Hawk, Lynn M. Matrisian, William G. Nelson, Gary S. Dorfman, Lisa Stevens, Jennifer Kwok, Jaye Viner, Judith Hautala, and Oren Grad

Translational Research Working Group Developmental Pathway for Biospecimen-Based Assessment Modalities
Sudhir Srivastava, Joe W. Gray, Brian J. Reid, Oren Grad, Addison Greenwood, and Ernest T. Hawk

The Translational Research Working Group Developmental Pathway for Image-Based Assessment Modalities
Gary S. Dorfman, Daniel C. Sullivan, Mitchell D. Schnall, and Lynn M. Matrisian

The Translational Research Working Group Developmental Pathway for Anticancer Agents (Drugs or Biologics)
Richard L. Schilsky, Gary Gordon, Tona M. Gilmer, Sara A. Courtneidge, Lynn M. Matrisian, Oren Grad, and William G. Nelson

Translational Research Working Group Developmental Pathway for Immune Response Modifiers
Martin A. Cheever, Jeffrey Schlom, Louis M. Weiner, H. Kim Lyerly, Mary L. Disis, Addison Greenwood, Oren Grad, and William G. Nelson

The Translational Research Working Group Developmental Pathway for Interventive Devices
Gary S. Dorfman, Theodore S. Lawrence, and Lynn M. Matrisian

The Translational Research Working Group Developmental Pathway for Lifestyle Alterations
Ernest T. Hawk, Addison Greenwood, Ellen R. Gritz, Anne McTiernan, Thomas Sellers, Stephen D. Hursting, Scott Leischow, and Oren Grad

Back to top


CCR Focus Cover

Phase 0 Trials
June 15, 2008
Guest Editor: James Doroshow, 14 (12) : 3643–4025

From the Editor
Susan E. Bates

Oncologic Phase 0 Trials Incorporating Clinical Pharmacodynamics: from Concept to Patient
James H. Doroshow and Ralph E. Parchment

The Development of Phase I Cancer Trial Methodologies: the Use of Pharmacokinetic and Pharmacodynamic End Points Sets the Scene for Phase 0 Cancer Clinical Trials
A. Hilary Calvert and Ruth Plummer

Leveraging Exploratory Investigational New Drug Studies to Accelerate Drug Development
David Jacobson-Kram and George Mills

Designing Phase 0 Cancer Clinical Trials
Anthony J. Murgo, Shivaani Kummar, Larry Rubinstein, Martin Gutierrez, Jerry Collins, Robert Kinders, Ralph E. Parchment, Jiuping Ji, Seth M. Steinberg, Sherry X. Yang, Melinda Hollingshead, Alice Chen, Lee Helman, Robert Wiltrout, Joseph E. Tomaszewski, and James H. Doroshow

Phase 0 Trials: An Industry Perspective
Helen Eliopoulos, Vincent Giranda, Robert Carr, Rita Tiehen, Terri Leahy, and Gary Gordon

Patient Perspectives on Phase 0 Clinical Trials
Martin Gutierrez and Deborah Collyar

The Ethics of Phase 0 Oncology Trials
Emily Abdoler, Holly Taylor, and David Wendler

Back to top


CCR Focus Cover

New Cytotoxics in Oncology
March 15, 2008
Guest Editor: Beverly Teicher, 14 (6) : 1599–1921

From the Editor
Susan E. Bates

Newer Cytotoxic Agents: Attacking Cancer Broadly
Beverly A. Teicher

The Epothilones: Translating from the Laboratory to the Clinic
James J. Lee and Sandra M. Swain

Vinflunine: A New Microtubule Inhibitor Agent
Jaafar Bennouna, Jean-Pierre Delord, Mario Campone, and Laurent Nguyen

Current Status and Future Prospects for Satraplatin, an Oral Platinum Analogue
Hak Choy, Clinton Park, and Min Yao

Aurora Kinases as Anticancer Drug Targets
Oliver Gautschi, Jim Heighway, Philip C. Mack, Phillip R. Purnell, Primo N. Lara, Jr., and David R. Gandara

Proteasome Inhibitors in Cancer Therapy: Lessons from the First Decade
Robert Z. Orlowski and Deborah J. Kuhn

Close Modal

or Create an Account

Close Modal
Close Modal